Trending Topic

Human heart with red cardio pulse line. Creative stylized red heart cardiogram with human heart on black background. Health, cardiology, cardiovascular diseases concept
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Cardiovascular disease (CVD) is a significant cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). An estimated 60–80% of patients with T2DM die of cardiovascular events.1,2 A bidirectional relationship has been noted between heart failure (HF) and T2DM.3 HF was noted to be twice as high in male patients and five times as […]

25 mins

Efficacy of Commonly Used 3D Mapping Systems in Acute Success Rates of Catheter Ablation Procedures

George Bazoukis, Khaled Elkholey, Stavros Stavrakis, E Kevin Heist, Antonis A Armoundas
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Apr 4th 2024 Heart International. 2024;18(1):9-25 DOI: 10.17925/HI.2024.18.1.3
Select a Section…
1

Abstract

Overview

Introduction

This systematic review aims to summarize the procedural arrhythmia termination rates in catheter ablation (CA) procedures of atrial or ventricular arrhythmias using the commonly used mapping systems (CARTO, Rhythmia and EnSite/NavX).

Materials and Methods

A systematic search in MEDLINE and Cochrane databases through February 2021 was performed.

Results

With regard to atrial fibrillation ablation procedures, acute success rates ranged from 15.4 to 96.0% and 9.1 to 100.0% using the CARTO and EnSite/NavX mapping systems, respectively; acute atrial tachycardia (AT) termination to sinus rhythm ranged from 75 to 100% using the CARTO system. The acute success rate for different types of AT ranged from 75 to 97% using Rhythmia, while the NavX mapping system was also found to have excellent efficacy in the setting of AT, with acute arrhythmia termination rates ranging from 73 to 99%. With regard to ventricular tachycardia, in the setting of ischaemic cardiomyopathy, acute success rates ranged from 70 to 100% using CARTO and 64% using EnSite/NavX systems. The acute success rate using the Rhythmia system ranged from 61.5 to 100.0% for different clinical settings.

Conclusions

Mapping systems have played a crucial role in high-density mapping and the observed high procedural success rates of atrial and ventricular CA procedures. More data are needed for the comparative efficacy of mapping systems in acute arrhythmia termination, across different clinical settings.

Keywords
2

Article

Catheter ablation (CA) is an invasive adjunctive therapeutic option for atrial and ventricular arrhythmias, in uncontrolled cases, following optimal medical therapy.1,2 The validation of 3D mapping and its implementation into clinical usage has been a remarkable achievement in the field of complex ablation of scar-related ventricular tachycardia (VT) in the early 2000s.3 In the setting of atrial fibrillation (AF), 3D navigation systems have been crucial for reducing complications, including pulmonary vein (PV) stenosis, perforation, phrenic nerve or oesophageal injury, during pulmonary vein isolation (PVI), or substrate modification, defragmentation or linear ablations, during chronic AF ablation.4–6

While clinical characteristics and the operators’ experience can affect long-term success rates of CA, the acute success rate is less dependent on clinical variables during the follow-up period, and therefore, it is a better marker of the efficacy of the different mapping systems.7–9 This systematic review aims to summarize the existing data about the acute arrhythmia termination success rates in atrial and ventricular CA procedures using the most common mapping systems (CARTO [Biosense Webster Inc., Diamond Bar, CA, USA], Rhythmia [Boston Scientific, Natick, MA, USA], CardioInsight [Medtronic Inc, Minneapolis, USA] and NavX/EnSite [St. Jude Medical, St Paul, Minnesota, USA]).

Materials and methods

This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.10

Search strategy

This study aimed to identify all relevant studies that provided data about the acute success rates of different mapping systems in patients who underwent the CA procedure either for AF and atrial tachycardia (AT) or for VT and premature ventricular contractions (PVCs). Two independent investigators performed a systematic search in MEDLINE and Cochrane databases through July 2021. The reference lists of the included studies, as well as relevant review studies, were manually searched. The following keywords were used to retrieve all relevant studies: “(CARTO OR Rhythmia OR NavX OR CardioInsight OR EnSite) AND (atrial OR ventricular) AND (fibrillation OR tachycardia OR flutter)”, without any limitations. We first screened the titles and abstracts of each retrieved study, and if a study was considered relevant, then the full text was studied.

Inclusion/exclusion criteria

We included studies that provided data on acute success rates during ablation procedures in either AF/AT or VT/PVCs across the different mapping systems. Acute success is defined either as clinical arrhythmia termination or as any arrhythmia termination or non-inducibility. The definitions of arrhythmia termination that were used in each study are presented in Tables 1 and 2.

Table 1: Baseline characteristics and main outcomes of the included studies related to atrial arrhythmia catheter ablation procedures

Study (year)

Country

Single/multicentre

N

Type of arrhythmia

Mean age (years)

Males (%)

EF (%)

Mapping system

Acute success, N (%)

Acute success definition

Mapping technique

Catheter type

Complications

Follow-up (months)

Recurrence at the f/u (%)

Fluoroscopy time (min) mean ± SD

Atrial arrhythmias

CARTO mapping system

Calvo et al. (2017)11

Spain

Single

13

Pers AF (long standing)

53.9

100

57.7

CARTO

2 (15.4)

SR restoration

Phase/frequency mapping

Irrigated NaviStar ThermoCool SmartTouch, PentaRay and a quadripolar catheter (Biosense Webster)

No complications

12–72

30

17.7±3.9

Choo et al. 2011*12

UK

Single

47

PAF and Pers AF

56.2

68

58.9

CARTO

45 (96)

SR restoration

Irrigated (Celsius or NaviStar ThermoCool [Biosense Webster] or Cool Path Duo [St. Jude Medical, St. Paul, MN, USA])

Cardiac tamponade (n=1)

12

60

73±27

Nademanee et al. (2004)13

Thailand

Single

121

PAF and Perm AF

63

76

n/a

CARTO

115 (95)

Complete elimination of the areas with CFAEs or conversion of AF into normal SR for patients with both CAF and PAF

Voltage maps

Standard 4 mm tip catheter

Cerebrovascular accident (n=1), cardiac tamponade (n=2), complete atrioventricular block (n=1), transient severe pulmonary oedema (n=1) and femoral arterial atrioventricular fistula (n=1)

12

9

14.7±4.8

Seitz et al. (2011)14§

EU

Single

22

NPAF: 86.4%

56.6

82

44.7

CARTO (Biosense Webster, Diamond Bar, CA, USA)

21 (95.5%

AF termination defined as the conversion of AF into SR or regularization into stable AT

CFAE LA map

2–5–2 mm electrode spacing (Xtrem; ELA Medical, Le Plessis-Robinson, France), 3.5 mm irrigated-tip quadripolar ablation catheter (2–5–2 mm interelectrode spacing, ThermoCool; Biosense Webster)

None

12

18

39±15

Seitz et al. (2013)14§

EU

Single

32

NPAF: 90.6%

60.4

75

52.6

CARTO (Biosense Webster)

30 (93.7)

AF termination defined as the conversion of AF into SR or regularization into stable AT

CFAE LA map

Decapolar catheter (2–5–2 mm electrode spacing, Xtrem; ELA Medical), 3.5 mm irrigated-tip quadripolar ablation catheter (2–5–2 mm inter-electrode spacing, ThermoCool [Biosense

Webster] F or J curve)

None

12

15.6

31±17

Suleiman et al. (2007)15

Israel

Single

13

AF

49

59

n/a

CARTO system (Biosence Webster, Johnson & Johnson, USA)

12 (92)

Termination to SR

Transient cerebrovascular accident (n=1)

33* refers to the total population

38.5

10.3±6.9* refers to the total population

Takahashi et al. (2018)16

Japan

Single

68

AF

62

68

59

CARTO 3 (Biosense Webster)

35 (51.5)

Termination into SR

Activation mapping

NaviStar ThermoCool SF catheter (Biosense Webster)

None

17.3

42.7

n/a

Wang et al. (2009)17

China

Single

111

Pers AF

50.8

55.9

53.1

CARTO (Biosense Webster)

SR → 30 (27)

AT → 35 (31.5)

Termination to SR or AT (both data are provided)

Activation mapping and CFAE mapping

Decapolar catheter (Biosense Webster), decapolar circular mapping catheter (Lasso; Biosense Webster) and saline-irrigated 3.5 mm catheter (ThermoCool NaviStar; Biosense Webster)

Catheter entrapment in valve prosthesis without further complications (n=1) and major stroke (n=1)

4.1 med

46.9

24±15

Wnuk-Wojnar et al. (2005)18

Poland

Single

94

PAF: 63.8%

54.3

64.9

58

CARTO (Johnson/Biosense Webster)

65 (69.6)

Termination to SR

Disappearance of electrical potentials within ablation lines and consequently inability to induce and maintain AF

n/a

Stroke (n=1), PV thrombosis (n=1), HIT (n=2) and pericardial tamponade (n=2)

12 med

30

22.4 (11–41)

Wu et al. (2008)19

EU

Single

10

Pers AF

62.3

50

n/a

CARTOXP (Biosense Webster)

3 (30)

Termination of AF and/or prolongation of AFCL

CFAE mapping

4-polar distally circular catheter (OrbiterPV; C.R. Bard), octapolar reference catheter (XPTTM; C.R. Bard Electrophysiology, Lowell, MA, USA), 4 mm irrigated tip catheter (NaviStar ThermoCool; Biosense Webster)

n/a

n/a

n/a

n/a

Suleiman et al. (2007)15

Israel

Single

37

AFL

49

59

n/a

CARTO system (Biosence Webster, Johnson & Johnson)

35 (95)

Termination to SR

None

33* refers to the total population

10.8

10.3±6.9* refers to the total population

Esato et al. (2009)20

EU

Single

26 (12 CARTO, 14 NavX)

Macro-reentrant AT

59

76.9

56

CARTO (Biosense Webster, Inc.) or NavX (Endocardial Solutions, Inc., St. Paul, MN, USA)

26 (100%) for both systems

Tachycardia termination and non-inducibility

Entrainment

Irrigated, F-type irrigated-tip, NaviStar ThermoCool [Biosense Webster]; M-Curve IBI Therapy Cooled Path [St. Jude Medical])

No complications

10.1

12

37±19

Jamil-Copley et al. (2013)21

UK

Single

10

AT

57.7

70

n/a

CARTO-XP system (Biosense Webster, Haifa, Israel)

9 (90)

Increase in TCL

Ripple, activation and entrainment

n/a

n/a

n/a

n/a

Okumura et al. (2016)22

Japan

Single

6

AT

67

33.3

n/a

CARTO 3 system (Biosense Webster)

6 (100)

Termination of AT and no inducibility of AT after isoproterenol infusion

Activation and entrainment

7F 4 mm tip (NaviStar; Biosense Webster), 5F quadripolar catheter (5–5–5 mm, inquiry catheter; St. Jude Medical), 5F decapolar catheter (Fe-po; Fukuda Denshi Co., Ltd., Tokyo, Japan) and 7F steerable duodecapolar Halo catheter (inquiry catheter; St. Jude Medical)

None

11

0

n/a

Suleiman et al. (2007)15

Israel

Single

20

AT

49

59

n/a

CARTO system (Biosence Webster, Johnson & Johnson)

15/20 (75)

Termination to SR

None

33* refers to the total population

25

10.3±6.9* refers to the total population

Strisciuglio et al. (2019)23

EU

Single

31

AT

69

63

n/a

CARTO

SR →23 (66)

AT → 12 (34)

AT termination to SR or AT with different cycle lengths

High-density activation mapping and entrainment mapping

Multi-electrode mapping catheter (PentaRay; Biosense Webster Inc., Irvine, CA, USA) and an open-tip irrigated RF catheter (8F) with tip-integrated contact force sensor (ThermoCool SmartTouch; Biosense Webster Inc.)

n/a

n/a

n/a

n/a

Vicera et al. (2020)24

Taiwan

Single

20

AT

58.2

75

59.6

CARTO 3 system ConfiDENSE Module

SR → 18 (69.2) Another AT → 7 (26.9)

Termination or change to a different activation pattern with an associated change in cycle length and negative inducibility of clinical AT

Activation mapping and coherent map

Multielectrode mapping catheter (Lasso Nav or PentaRay Nav; Biosense Webster, Inc.)

n/a

13.7

25

n/a

Wo et al. (2014)25

Taiwan

Single

15

AT

49

66.7

62

CARTO (Biosense Webster)

15 (100)

Termination of MRAT and non-inducibility

Entrainment mapping

4 mm NaviStar catheter (irrigating or non-irrigating; Biosense Webster)

n/a

15

0

n/a

Yagishita et al. (2019)26

Japan

Single

39

AT

65

78

59

CARTO 3 ConfiDENSE Module (Biosense Webster)

90

Termination to SR

LAT, voltage and entrainment

Mapping catheter (PentaRay Nav; Biosense Webster), 3.5 mm irrigation catheter (ThermoCool; Biosense Webster)

n/a

n/a

n/a

n/a

Rhythmia mapping system

Kitamura et al. (2018)27

EU

Two-centre

8

Biatrial AT

59.5

87.5

59.9

Rhythmia (Boston Scientific, Marlborough, MA, USA)

8 (88.9)

Termination of biatrial AT to SR or to another AT

High-density activation map

3.5 mm tip open-irrigated catheter (ThermoCool SF; Biosense Webster), decapolar catheter within the coronary sinus (Extreme, Sorin/Dynamic XT; Boston Scientific)

n/a

12.4 med

12.5

n/a

Yamashita et al. (2019)28

EU and Japan

Multicentre

26

Post-AF ablation AT

63

69

57

Rhythmia (Boston Scientific)

25 (96.2)

Restoration of SR or a change in the AT by RF ablation of the PV gap

Activation and entrainment

64-pole mini-basket catheter (Orion; Boston Scientific), non-magnetic open-irrigated catheter (Celsius, ThermoCool; Biosense Webster, Inc.)

n/a

12

15

n/a

Anter et al. (2016)29

US

Multicentre

20

Recurrent AT

62

n/a

n/a

Rhythmia (Boston Scientific, Cambridge, MA, USA)

18 (75)

Termination to SR

Activation, entrainment and pace

Orion basket catheter (Boston Scientific), nonmagnetic open-irrigated catheter (Celsius, ThermoCool; Biosense Webster)

None

7.5

25

n/a

De Simone et al. (2020)30

EU

Single

24

Re-entrant AT

54

54.2

n/a

Rhythmia (Boston Scientific, Inc.)

96.2

Termination to SR

Propagation map and entrainment

64-pole mini-basket mapping catheter (IntellaMap Orion; Boston Scientific, Inc.)

None

18

12.5

n/a

Laţcu et al. (2017)31

EU

Single

19

AT

71 med

68.4

62 med

Rhythmia (Boston Scientific)

29 (97)

Termination into SR or another stable AT

Activation maps

Decapolar diagnostic catheter (Inquiry L, 2–5–2 mm spacing; Saint Jude Medical), F-type, 2–8–2 mm spacing (Biosense Webster) and an IntellaMap Orion mapping catheter

None

12 med

16

18±10

Takigawa et al. (2017)32

EU

Single

57

AT

61.9

82.5

54.3

Rhythmia (Boston Scientific, Natick, MA, USA)

66/88 (75)

AT termination

Activation and entrainment

Orion multipolar basket catheter (Boston Scientific), 3.5 mm tip ablation catheter (ThermoCool SF catheter; Biosense Webster)

n/a

6

26.3

n/a

Takigawa et al. (2018)33

EU

Single

41

Post-AF ablation AT

65.7

70.7

52.6

Rhythmia system (Boston Scientific)

80.6

AT termination

Activation

Orion multipolar basket catheter, 3.5 mm tip ablation catheter (ThermoCool SF; Biosense Webster)

n/a

12

45.2

n/a

NavX–EnSite mapping systems

Aksu et al. (2020)34

Turkey and USA

Single

12

Pers AF

53

83

48.5

EnSite Precision (Abbott Medical, Chicago, IL, USA)

8 (66.7)

SR restoration

Fractionation and mapping

3.5 mm tip ablation catheter (TactiCath™ or FlexAbility™; Abbott), 20-pole spiral double-loop catheter (Inquiry™, AFocus II™ [Abbott]; 1 mm length, 4 mm spacing, 20 mm fixed-loop diameter)

n/a

34 med

25

n/a

Miyamoto et al. (2009)35

Japan

Single

50

Pers AF: 20%

61.2

74

n/a

EnSite version 6.0J (St. Jude Medical)

75.6

AF termination to SR during PVAI alone or additional RF ablation

Voltage and activation maps

8 mm tip ablation catheter

n/a

14

8%

n/a

Miyamoto et al. (2010)36

Japan

Single

20

Pers AF: 20%

58

70

n/a

EnSite version 6.0J (St. Jude Medical)

14 (70)

AF termination to SR

CFAE ablation

7F catheter with an 8 mm tip distal electrode (Fantasista; Japan Lifeline Co. Ltd., Tokyo, Japan)

n/a

n/a

n/a

n/a

Yamaguchi et al. (2010)37

Japan

Single

65

PAF

58

84.6

n/a

EnSite array

47/51 (92.2)

AF termination to SR

Activation map

20-pole circular mapping catheter (Optima; St. Jude Medical) and deflectable 7F quadripolar, non-irrigated 8 mm tip electrode ablation catheter (Fantasista; Japan Lifeline)

No complications

23

16.9

n/a

Ammar-Busch et al. (2018)38

EU

Single

16

Pers AF

63

88

n/a

NavX (St. Jude Medical), ECVUE™ (CardioInsight Technologies, Inc., Cleveland, OH, USA)

12 (75)

AF termination

CFAE mapping

14 bipoles Orbiter PV, C. R. Bard or 20 bipoles AFocus II™ [St. Jude Medical], irrigated tip catheter (Therapy™ Cool Flex™; St. Jude Medical)

No complications

n/a

n/a

n/a

Kumagai et al. (2013)39

Japan

Single

50

PAF and Pers AF

63.9

78

61

NavX system (NavX, with CFE software; St. Jude Medical Inc.)

18 (36)

Termination to SR

CFAE, activation and mapping

7 F decapolar circular catheter (Lasso; Biosense Webster, Inc) and 3.5 mm irrigated tip RF catheter (Safire; St. Jude Medical Inc.)

n/a

12

28

n/a

Kumagai et al. (2017)40

Japan

Single

32

AF

57

87.5

63

NavX system (NavX with CFE software; St. Jude Medical Inc.)

26 (81.3)

AF termination or >10% slowing of the AF cycle length from after the PVI to the end of the high-DF and continuous CFAE-site ablation

CFAE, activation and mapping

7F decapolar circular catheters (Lasso; Biosense Webster, Inc.), 3.5 mm irrigated tip radiofrequency catheter (Safire; St. Jude Medical Inc.) and a 20-pole mapping circular catheter (St. Jude Medical Inc.)

No complications

12

19

n/a

Choo et al. (2011)*12

UK

Single

24

PAF and Pers AF

62.2

71

55.4

NavX

24 (100)

SR restoration

Irrigated (Celsius or NaviStar ThermoCool [Biosense Webster] or Cool Path Duo [St. Jude Medical])

Pulmonary vein puncture (n=1)

79±25

Lin et al. (2009)41

Japan

Single

60

NPAF

49

83.3

55

NavX (with CFE software; St. Jude Medical Inc.)

20/60 (33.3)

AF restored to SR during ablation

CFE mapping

Irrigated-tip 4 mm ablation catheter (EPT; Boston Scientific Corporation), circular catheter recording (Spiral, AF Division; St. Jude Medical Inc.)

Patient with cardiac tamponade (n=1)

19

25

n/a

Lo et al. (2009)42

Japan

Single

87

Perm AF

53

82.8

54

NavX (St. Jude Medical)

30 (34.5)

Termination to SR

CFAE mapping

Irrigated-tip 3.5 mm ablation catheter (Chilli II™, EPT; Boston Scientific Corporation, San Jose, CA, USA) and catheter recording (Spiral, AF Division; St. Jude Medical)

Pericardial effusion needing pericardiocentesis (n=1)

21

21

n/a

Matsuo et al. (2012)43

Japan

Single

40

Pers AF

53.5

97.5

62.4

EnSite NavX (St. Jude Medical)

13 (32.5)

Termination to SR

CFAE mapping

16-polar tow site (6-polar for the right atrium and 10-polar mapping catheter [Inquiry Luma-Cath; St. Jude Medical]), 20-polar circumferential mapping catheter of 20, 25 or 30 mm in diameter (Inquiry Optima; St. Jude Medical or Lasso, Biosense Webster) and irrigated 3.5 mm tip ablation catheter (CoolPath™ Duo [St. Jude Medical] or ThermoCool NaviStar [Biosense Webster])

n/a

19.7

20

n/a

Nair et al. (2009)44

India

Single

21

Perm AF

44

42.9

n/a

NavX EnSite software, version 7, at St. Jude Medical

18 (85.7)

Organization of the atrial electrograms or conversion into an SR

CFAE mapping and voltage maps

2 mm irrigated tip ablation catheter (IBI Therapy Cool Path Ablation Catheter; Irvine Biomedicals, Irvine, CA)

No complications

9.8

23.1

n/a

Nakahara et al. (2014) 45

Japan

Single

60

Pers AF

63.1

83

59

NavX, with CFE software (St. Jude Medical, Inc.)

19 (31.7)

Termination of AF to SR directly or via one or more intermediate ATs

CFAE mapping

20-pole, 15–25 mm Lasso catheter with 6 mm bipole spacing (Biosense Webster), 4 mm irrigated-tip catheter (Safire; St. Jude Medical) and 20-pole, 20 mm AFocus II catheter with 4 mm bipole spacing; St. Jude Medical)

n/a

16 med

21.7

44.8±8.1

Roux et al. (2009)46

USA

Single

22

Pers AF

58

82

60

NavX system (NavX, St. Jude Medical)

2 (9.1)

AF termination with PVI

CFΑE mapping

Mapping catheter (10-pole, 15–25 mm Lasso, 6 mm bipole spacing; Biosense Webster) and an 8 or 3.5 mm irrigated-tip catheter (Biosense Webster)

n/a

n/a

n/a

99±35

Suenari et al. (2011)47

Taiwan

Single

23

PAF

54.3

83

59

EnSite NavX (St. Jude Medical, Inc.)

16/23 (69.6)

Termination of AF to SR directly or through one or more intermediate ATs

CFAE mapping

Irrigated 3.5 mm tip ablation catheter (EPT; Boston Scientific Corporation), 7F 10-pole/6F 4-pole catheters (St. Jude Medical Inc.) and 5F 12-pole circular catheter (Spiral, AF Division; St. Jude Medical Inc.)

n/a

11.9

24

n/a

Verma et al. (2011)48

US

Single

30

Pers AF

63

75

52

EnSite NavX mapping system (St. Jude Medical)

4 (13.3)

3 (10%) (termination to SR)

AF termination to SR or AT

CFAE mapping

Circular mapping catheter with ten 2 mm electrodes and 2 mm interelectrode spacing (Lasso; Biosense Webster) and 3.5 mm tip ablation catheter (ThermoCool; Biosense Webster)

Left femoral haematoma (n=1)

12

43

55±20

Narita et al. (2010)49

Japan

Single

51

AT

57

54.9

n/a

EnSite Multielectrode array (version 3.2 in 33 patients; version 6.0J in 18 patients)

99

AT termination to SR and subsequent non-inducibility

Voltage and activation maps

A 4 or an 8 mm tip steerable catheter (Fantasista [Japan Lifeline]; Blazer II [Boston Scientific])

No complications

16

3.9

19±11

Patel et al. (2008)50

USA

Single

17

Post-AF ablation AT

62

82.4

61

EnSite NavX

96

AT termination to SR and non-inducibility

Activation and entrainment

3.5 mm-tip Celsius ThermoCool (Biosense Webster, Inc.) or Chili (Boston Scientific, Inc.), mapping catheter (Lasso or Optima catheters; Biosense Webster, Inc., and St Jude Medical, Inc.), PentaRay catheter is a 20-pole steerable mapping catheter arranged in five soft radiating spines (1 mm electrodes separated by 4, 4 and 4 mm interelectrode spacing) covering a diameter of 3.5 cm (PentaRay; Biosense Webster, Inc.) and irrigated ablation catheter

No complications

7

23.5

n/a

Nagamoto et al. (2011)51

Japan

Single

33

Post-AF ablation AT

59

n/a

n/a

EnSite version 6.0J (St. Jude Medical)

24 (73)

Termination of AT or change to another AT or non-inducibility

CFAE ablation

Livewire (St. Jude Medical), multielectrode array catheter (St Jude Medical), 20-pole circular electrode catheter (Optima; St. Jude Medical) and non-irrigated ablation catheter with an 8 mm tip (Fantasista; Japan Lifeline)

Femoral arteriovenous fistula (n=1)

21

9

n/a

*Choo’s study provided separate data about the patient characteristics for CARTO and NavX mapping systems.

Suleiman’s study provided data on AF, AFL and AT, while the baseline characteristics are provided only for the total population.

The denominators in these percentages are the total number of atrial arrhythmias and not the total number of the included patients.

§These are similar cohorts, and therefore, these data were used once in the quantitative synthesis.

AF = atrial fibrillation;AFL = atrial flutter;AT = atrial tachycardia;CFAE = complex fractionated atrial electrogram;EF = left ventricular ejection fraction;F = French;f/u = follow-up;Med = median;n/a = not available;NPAF = non-paroxysmal AF;PAF = paroxysmal AF;Perm AF permanent AF;Pers AF = persistent AF;PV = pulmonary vein;PVAI = pulmonary vein isolation ablation;PVI = pulmonary vein isolation;SR = sinus rhythm.

Table 2: Baseline characteristics and main outcomes of the included studies related to ventricular arrhythmia catheter ablation procedures

Study (year)

Country

Single/multicentre

N

Mean age (years)

Males (%)

Clinical setting

EF (%)

Mapping

system

Mapping

type

Acute success/definition of success

Complications (n)

Catheter

Follow up (months)

Recurrence at follow up (%)

Endo or epi or both

Fluoroscopy time (min) mean±SD

Ventricular tachycardia – PVCs

CARTO mapping system

Luther et al. (2016)52

UK

Single

15

68 med

n/a

Ischaemic

CMP

30

CARTO 3v4 (Biosense Webster, Diamond Bar, CA, USA)

Ripple, voltage, point by point or using an automated point collection facility (ConfiDENSE Continuous mapping)

85% (non-inducible in 2/15 at the beginning)

None

Μultielectrode PentaRay catheter; 3.5 mm tip SmartTouch ThermoCool catheter (Biosense Webster)

6 med

71

Endo

n/a

Marai et al. (2010)53

Israel

Single

11

71

100

Ischaemic

CMP

23

CARTO mapping and navigation system (Biosense Webster, Johnson & Johnson, USA)

Pace and entrainment, activation, voltage and substrate

82% (termination of clinical VT and/or non-inducibility)

n/a

Open-irrigated ablation catheter

3

11.1

Endo

n/a

Volkmer et al. (2006)54

EU

Single

47

65

91.5

Ischaemic

CMP

30

CARTO

Activation, voltage, substrate, entrainment and pace

79.1% (non-inducibility of the clinical or any slower VT)

n/a

4 mm tip (NaviStar™) or a 3.5 mm irrigated tip electrode (NaviStar ThermoCool™; Biosense Webster Ltd), RefStar™; (Biosense Webster Ltd.)

25.1

43.2

Endo

23.7±19.2

Antz et al. (2007)55

EU

Single

69

66.2

88.4

Ischaemic

CMP

32.6

CARTO system (Biosense Webster, Inc.)

Voltage, entrainment and pace

90% (non-inducibility of the clinical or slower VT), 43 (63%) (non-inducibility of any VT)

n/a

Quadripolar 6F Josephson catheter (Biosense Webster, Inc.), decapolar 6F Parahis catheter (Biosense Webster, Inc.), 7F CARTO catheter, either non-irrigated (4 mm tip; NaviStar; Biosense Webster Ltd.) or irrigated (3.5 mm tip; NaviStar ThermoCool; Biosense Webster Ltd.)

25

37.7

Endo

24±13.5

Bogun et al. (2005)56

US

Single

23

68

n/a

Ischaemic

CMP

21

CARTO, Biosense Webster Inc.)

Voltage map

74% of VTs (targeted VT was successfully ablated)

n/a

NaviStar catheter (Biosense Webster Inc.)

n/a

n/a

Endo

n/a

Brunckhorst et al, (2004)57

US

Single

11

68

100

Ischaemic

CMP

24

CARTO (Biosense Cordis Webster)

Voltage, pace and entrainment

90.9% (successful ablation sites were localized within an isthmus identified by pace mapping)

45.5% (absence of inducible VT)

45.5% (absence of inducible clinical VT)

n/a

n/a

n/a

n/a

Endo

n/a

Deneke et al. (2005)58

EU

Single

25

62

n/a

Ischaemic

CMP

37

CARTOTM System (Biosense Webster®)

Substrate map, voltage mapping and pace

70% (no VT inducible)

Patients without procedural success (epicardial origin-problematic access to the LV) (n=2)

NaviStar DS catheter

10

17.4

Endo

n/a

Dinov et al. (2012)59

EU

Single

102

67.7

86.3

Ischaemic

CMP

32

Niobe Stereotaxis magnetic navigation system (Stereotaxis Inc.), electroanatomical mapping system (CARTO-RMT; Biosense Webster, Inc.) or EnSite-NavX (St. Jude Medical Inc., St. Paul, MN, USA)

Substrate and/or activation mapping entrainment pace

96% (successful ablation of the clinical VT)

76.5% (successful ablation of all inducible monomorphic sustained VTs)

Pseudoaneurysm (n=2), arteriovenous fistula (n=1), pericardial effusions (n=6) and liver injury (n=1)

Irrigated-tip catheter (NaviStar ThermoCool; Biosense Webster Inc.) and irrigated-tip catheter (NaviStar ThermoCool-RMT; Biosense Webster Inc. or Trignum Flux Gold, Biotronik, Berlin, Germany)

14 med

26.9

Endo–epi in one patient

n/a

Kettering et al. (2010)60

EU

Single

7

66.6

n/a

Ischaemic

CMP

32.1

CARTO system (Biosense Webster)

Voltage and pace

100% (elimination of all clinically documented or inducible VTs)

No major complications

6F quadripolar diagnostic catheter (Biosense Webster), irrigated-tip ablation catheter (NAVI-STAR, 7F, D- [or C-] type, 3.5 mm-tip; Biosense Webster) and 8 mm-tip ablation catheter (7F, mostly C-curve; Biosense Webster

19

28.6

Endo

n/a

Li et al. (2006)61

EU and China

Single

14

65

92.9

Ischaemic

CMP

29

CARTO, NAVI-STAR (Cordis-Webster, Johnson and Johnson)

Substrate, voltage, pace and entrainment

78.6% (no VT inducibility)

n/a

NaviStar, ThermoCool (Cordis-Webster)

7

21.4

Endo

10±7

Jamil-Copley et al. (2015)62

EU

Single

21

69

95

Ischaemic

CMP

28

CARTO-3 (Biosense Webster Inc.)

Voltage, LAT, entrainment, ripple

19,1% (termination during ablation)

78% (non-inducibility)

n/a

5 mm NaviStar ThermoCool catheter (Biosense Webster Inc.)

15.5

29

Endo

n/a

Verma et al (2005)63

USA

Single

46

65

89.1

Ischaemic

CMP

27

CARTO (Biosense Webster, Inc.)

Activation, voltage and entrainment

100% (identification of the successful ablation sites)

Periprocedural stroke (n=1), femoral haematoma (n=1), femoral pseudoaneurysm (n=1) and prolonged hypotension (n=1)

7F NaviStar (Biosense Webster, Inc.)

17 med

36.9

Endo–epi

n/a

Miyamoto et al. (2015)64

Japan

Single

11

59

24

Ischaemic, dilated CMP, sarcoidosis and HCM

24

CARTO version 3 or XP

Voltage, activation, entrainment and pace

45.5% (VT termination and non-inducibility)

n/a

Open-irrigated tipped catheter, ThermoCool® (Biosense Webster, Johnson & Johnson)

21

Endo–epi

n/a

Yamashina et al. (2009)65*

Japan

Single

72

43.6

44.4

Idiopathic

RVOT

n/a

CARTO system (Biosense Webster)

Activation, voltage and pace

63 (87.5%) (absence of any spontaneous or induced clinical RVOT arrhythmias and no recurrence of any symptomatic ventricular arrhythmia)

n/a

7 F NaviStar (Biosense Webster)

n/a

n/a

Endo

n/a

Suleiman et al. (2007)15

Israel

Single

15

59

49

RVOT VT

n/a

CARTO

12 (80)

None

33* refers to the total population

26.7

10.3* refers to the total population

Parreira et al. (2013)66

EU

Single

32

43

25

Outflow

tract VT

n/a

CARTO XP RMT (Biosense Webster)

Pace mapping

26 (81%) (first procedure) (suppression and non-inducibility of arrhythmia)

None

NaviStar RMT (Biosense Webster), NaviStar RMT ThermoCool (Biosense Webster)

10.2

6.3

Endo

10±7.8

Yamashina et al. (2010)67*

Japan

Single

33

45.5

36.4

Outflow

tract VT

n/a

CARTO (Biosense Webster)

Activation and pace

87.9% (absence of any spontaneous or induced clinical RVOT arrhythmias and no recurrence of any symptomatic ventricular arrhythmia)

None

NaviStar (Biosense Webster) catheter

2

6.1%

Endo

n/a

Tovia-Brodie et al. (2016)68

Israel

Single

18

60

66.7

Idiopathic (77.8%) and ischaemic VT (22.2%) (complete abolition of the clinical ventricular arrhythmia or non-inducibility of ischaemic ventricular tachycardia)

48.6

CARTO Segmentation Module software (Biosense Webster)

Activation, pace and substrate mapping

Idiopathic: 78.6% and ischaemic: 100%

None

3.5 mm open-irrigated catheter (ThermoCool, SmartTouch; Biosense Webster)

n/a

n/a

Endo and epi for ischaemic VT

Ischaemic: 20.9±8.8 min and idiopathic: 22.95±12 min

Verma et al. (2005)69

USA

Single

22

41

68

ARVC

55

CARTO mapping system (Biosense Webster Inc.)

Voltage and pace

18 (82%) (non-inducibility of ablated VT or other sustained monomorphic VT)

Cardiac tamponade (1) and femoral haematoma (2)

7F 4 mm-tip deflectable ablation catheter (NaviStar; Biosense Webster Inc.)

37 med

36.4

Endo

83±47

Satomi et al. (2006)70

Japan

Single

17

47

76.5

ARVC

n/a

CARTO

Activation, voltage and pace

88% (no monomorphic VT was inducible)

No major complications

7F mapping/ablation catheter (NAVI-STAR; Cordis-Webstar, Johnson & Johnson)

26

23.5

Endo

n/a

Rhythmia mapping system

Martin et al. (2019)71

EU

Multicentre

27

64.3

85.2

Ischaemic and

dilated

CMP

36

Rhythmia

Substrate, activation, entrainment and pace

92.3% (non-inducibility)

No complications

Orion mapping catheter (Boston Scientific)

51.6

18.5

Endo–epi

44.4±12.4

Nührich et al. (2017)72

EU

Single

22

67

n/a

Ischaemic and non-ischaemic, ARVC

36

Rhythmia 3D electro-anatomical mapping system (Boston Scientific, Marlborough, MA, USA)

Voltage and activation

87% (non-inducibility)

Tamponade (n=1)

ThermoCool, D- or F-Type, 2–5–2 mm spacing (Biosense Webster) or Intella NAV OI; (Boston Scientific)

4

10

Endo–epi

20.7±1.6

Sultan et al. (2019)73

EU

Single

32 (VT 15 patients and VE 17 patients)

63

90.6

Different clinical settings including ischaemic CMP and myocarditis

47,2

IntellaMap Orion™ Mapping Catheter (Boston Scientific Corporation) in combination with the Rhythmia™ mapping system (Boston Scientific Corporation)

Activation, pace, substrate and entrainment

100% 9no inducibility)

Femoral haematomas (n=3)

Quadripolar diagnostic catheter (Inquiry™, 5 F, Fa.; Abbott), decapolar diagnostic catheter (Inquiry™, 6 F, Fa.; Abbott)

6

20

Endo

23.4±13.7

Viswanathan et al. (2016)74

EU

Single

19 (VT: 12 patients and VE: 7 patients)

64

79

Ischaemic and non-ischaemic CMP, congenital HD, hypertrophic CMP and normal

35

Rhythmia (Boston Scientific Inc.)

Activation

VE: 6/7 (86%)

VT procedures: 8/13 (61.5%) complete success (non-inducibility)

Femoral pseudoaneurysm (n=1) and groin haematoma (n=1)

64-electrode mini-basket mapping catheter (IntellaMap Orion™; Boston Scientific Inc.)

10

VT 25% VE: 14.3%

Endo–epi

41.8±17.5

NavX–EnSite–CardioInsight mapping systems

Lee et al. (2019)75

Taiwan

Single

28 (24 PVC and 4 VTs)

48.8

42.9

RVOT PVCs

or VT

70

EnSite NavX or Velocity V5.0 3D mapping system (Abbott)

Voltage, pace and activation

78.6% (at least an 80% decrease in PVC burden by 24 h Holter ECGs 3 months later after ablation)

1% pericardial effusion

7F 4 mm quadripolar irrigated ablation catheter or a 7F 4 mm or 8 mm non-irrigated ablation catheter

3

21.4

Endo

n/a

Nayyar et al. (2013)76

Australia

Single

22

67

95

Ischaemic

CMP

32

EnSite NavX (St. Jude Inc.)

Entrainment and pace

64%(no inducible VT after ablation, abolition of ≥1 clinical VTs with other VTs remaining inducible was considered a partial success and the inability to eliminate the clinical VT was considered as a failure)

n/a

3.5 mm tip irrigated ablation (CoolFlex [St. Jude] or ThermoCool [Biosense Webster]), 20-pole catheter (PentaRay; 2–6–2 mm interelectrode spacing) and 1 mm electrodes (Biosense Webster, Inc.)

16

22.7

Endo

n/a

Miyamoto et al. (2010)77

Japan

Single

55

52

49%

Organic heart disease:

7 patients and idiopathic VT:

48 patients

n/a

EnSite version 3.0 in 20 patients and version 6.0J in 35 patients

Voltage, substrate, activation and entrainment

95% (sustained VT was VT termination, subsequent non-inducibility of VT for focal VT and non-inducibility for non-sustained focal VT and PVC)

No complications

Quadripolar electrode catheter, 20-pole multielectrode catheters (St. Jude Medical, Minnetonka, MN, USA/Ten-Ten, St. Jude Medical)

21

Endo

30±21

Nair et al. (2011)78

India

Single

15

44

80

ARVC

n/a

EnSite array mapping and non-contact electroanatomical mapping

Activation, entrainment and pace

86.7% (all of the inducible VTs were successfully mapped and ablated)

No complications

25

13.3

Endo

n/a

Hocini et al. (2015)79

EU

Multicentre

24

45

58

Idiopathic PVCs and PVCs in the setting of HCM and ischaemic CMP

58.4%

3D mapping technique (ECVUE; CardioInsight Inc.)

Activation

100%

None

Quadripolar mapping catheter) and 4 mm tip ablation catheter (Biosense Webster)

24.7

4.2

Endo

8.8±1.5

*These were similar cohorts and, therefore, were included once in the quantitative synthesis.

The percentage refers to the number of successfully ablated VTs.

ARVC = arrhythmogenic right ventricular cardiomyopathy;CMP = cardiomyopathy;EF = ejection fraction;endo = endocardial;Epi = epicardial;F = French;HCM = hypertrophic cardiomyopathy;med = median;n/a = not available;PVCs = premature ventricular complexes;RVOT = right ventricular outflow tachycardia; VE = ventricular ectopy;VT = ventricular tachycardia.

We excluded studies that did not report data about the acute success rates or the type of mapping system that was used for the ablation procedure. Furthermore, we excluded studies including only patients with congenital heart diseases, heart transplant recipients and children. Case reports/series, animal studies, studies on ventricular fibrillation ablation procedures and studies on hybrid ablation procedures have also been excluded.

Data extraction

The data extraction was performed independently by two authors (GB and KE). The following data were extracted: first author, year of publication, journal name, type of study (single or multicentre), type of arrhythmia (AF, AT, VT or PVCs), duration of follow-up, number of patients, gender, age, type of cardiomyopathy, left ventricular ejection fraction, type of mapping system, type of catheters, mapping techniques, acute success definition, acute procedural success rates, procedural complications, follow-up, arrhythmia recurrence during follow-up, fluoroscopy time and type of ablation (endocardial, epicardial or combined).

The quality assessment of the included studies was performed using the NIH Quality Assessment Tool.80

Results

Study search

Of the 848 studies, 661 were excluded at the title/abstract level and 117 were excluded at the full-text level. Finally, 70 unique studies were included in the systematic review. Of them, 42 studies reported data about the acute procedural success of atrial CA procedures, while 29 studies provided data about the acute procedural success of ventricular CA procedures. One study provided data on both ventricular and atrial CA procedures.15 The search strategy is shown in Figure 1.

Figure 1: Flow diagram of the search strategy

Study characteristics

The baseline characteristics and the main findings of the included studies are presented in Tables 1 and 2 and in Figure 2.

Figure 2: Acute success rates and complications of commonly used mapping systems

AF = atrial fibrillation; AT = atrial tachycardia; CMP = cardiomyopathy; VT = ventricular tachycardia

With regard to atrial arrhythmias, the search strategy revealed 17 unique studies that used the CARTO mapping system.11–26 Specifically, 10 studies provided data about AF ablation, 1 study on atrial flutter (AFL) ablation and 8 studies on AT ablation (one study provided data on all three types of arrhythmias).11–26 The Rhythmia mapping system was used in seven studies on atrial arrhythmias (two AF studies and five AT studies).27–33 Finally, in the setting of atrial arrhythmias, 20 studies provided data on the NavX/EnSite mapping systems (16 AF studies and 4 AT studies – 2 studies also provided data on the CARTO mapping system and therefore were included in both systems).12,20,34–51 As each of AF, AFL and AT has distinct electrophysiological mechanisms and substrates, we elected to report outcomes for each of these arrhythmias separately.

In the setting of ventricular CA, the search strategy revealed 20 studies that used the CARTO mapping system (12 studies in patients with ischaemic cardiomyopathy, 4 studies on outflow tract VT, 2 studies in the setting of arrhythmogenic right ventricular cardiomyopathy [ARVC] and 2 studies in mixed population); 4 studies that used the Rhythmia mapping system in mixed population including ischaemic and non-ischaemic cardiomyopathy, hypertrophic cardiomyopathy and congenital heart diseases and 5 studies that used the NavX/EnSite and CardioInsight mapping systems (one study in patients with ischaemic cardiomyopathy, one study in patients with ARVC, one study in patients with outflow tract VT and two studies in mixed population).15,52–69,71–79

All studies achieved a good quality rating according to the National Heart, Lung and Blood Institute study quality assessment tool (Online Supplement Table S1).81

Outcome data

Atrial arrhythmias

CARTO mapping system

In the clinical setting of persistent AF, CARTO exhibited a variable performance (10 studies) in terms of acute arrhythmia termination (Table 1). Specifically, in this setting, the acute success rates ranged from 15.4 to 96%, depending mainly on the type of AF and the definition of acute success (termination to sinus rhythm [SR] or termination of AF to any other organized rhythms).11–14,16–19,82

Furthermore, in the included studies, CARTO was used for the management of AT (eight studies). In this setting, the acute termination of ATs to SR ranged between 75 and 100%.20–26 Similarly, one study showed that the acute termination rate for AFL was 95% (Table 1).15

Rhythmia mapping system

Our search identified seven studies that used the Rhythmia mapping system for guiding CA procedures in patients with AT. These data showed excellent efficacy in terms of acute arrhythmia termination rates (Table 1).27–33

Furthermore, the search strategy revealed that the acute success rate for different types of AT (seven studies) ranged from 75 to 97%.28–33

NavX/EnSite mapping systems

In the setting of AF ablation, the use of the NavX/EnSite mapping system resulted in acute arrhythmia termination rates (16 studies), ranging between 9.1 and 100%, depending mainly on the type of AF (Table 1).12,34–48 However, it should be mentioned that the study that showed the lowest arrhythmia termination rate provided data about arrhythmia termination with PVI only in patients with persistent AF.46

The NavX mapping system was also found to have excellent efficacy in the setting of AT (three studies), with acute arrhythmia termination rates ranging between 73 and 99% (Table 1).49–51,83

Ventricular arrhythmias

CARTO mapping system

The CARTO mapping system has been used for the management of ventricular arrhythmias (20 studies) in different clinical settings (Table 2).15,52–70 The identified studies showed that the CARTO mapping system had an excellent efficacy in ischaemic cardiomyopathy (12 studies) CA ablation procedures.52–63 Specifically, the acute success rates are defined as the absence of VT inducibility at the end of the procedure, which ranged from 70 to 100%.52–63

Furthermore, the CARTO mapping system showed excellent results with more than 80% acute success rate in outflow tract ventricular arrhythmias and in the setting of ARVC (four and two studies, respectively).15,65–67,69,70

Rhythmia mapping system

The search strategy revealed four studies on the acute arrhythmia termination rates using the Rhythmia mapping system in the setting of ventricular arrhythmias (Table 2). These studies showed excellent results in abolishing VT and ventricular ectopy in different clinical settings, including ischaemic and non-ischaemic cardiomyopathy, with acute success rates ranging from 61.5 to 100%.71–74

EnSite/NavX mapping systems

The search strategy revealed five studies on the success rates of the EnSite/NavX mapping system, mainly in the setting of patients with outflow tract ventricular arrhythmias, ischaemic cardiomyopathy and ARVC (Table 2).75–79 Specifically, acute success rates were found to be 78.6% in patients with outflow tract arrhythmias, 86.7% in patients with ARVC and 64% in patients with ischaemic cardiomyopathy.75–79

Discussion

Our review summarizes the acute success rates of the most popular mapping systems across different clinical settings. The existing evidence shows that the most commonly used mapping systems have excellent efficacy regarding acute arrhythmia termination outcomes in both atrial and ventricular arrhythmias, depending mainly on the type of arrhythmia and the clinical setting.

Cardiac mapping is an essential component in the understanding and treatment of arrhythmias through CA procedures. Activation and electrocardiographic signal amplitude mapping are the most frequent modalities in 3D mapping systems, while entrainment mapping can provide additional data in the setting of atrial or ventricular arrhythmias. The commonly used 3D mapping systems such as CARTO (Biosense Webster), EnSite Precision (Abbott) and, more recently, Rhythmia (Boston Scientific) systems have played a major role in enabling and facilitating the high-density mapping of complex arrhythmias.3 The in vitro and in vivo accuracy of the CARTO mapping system has been studied since 1997.84 The CARTO mapping system has been used to guide the ablation procedure in patients with different types of atrial arrhythmias, including AF, AFL and AT.11–14,16–26,82

Today, the CARTO 3 system consists of a location pad with three separate low-level magnetic field-emitting coils arranged as a triangle under the patient’s body and six-electrode patches positioned on the patient’s back and chest. The latest version relies on hybrid magnetic- and current-based localization technologies and has reported an accuracy of less than 1 mm.3 On the other hand, the current EnSite/NavX navigation and visualization technology consists of a set of three pairs of skin patches and a system reference patch, and uses hybrid impedance-based and magnetic-tracking technologies to create cardiac models or geometries, which display voltage data and activation timing. The Rhythmia mapping system, which uses a hybrid tracking technology using both magnetic- and impedance-based localization features for map creation, was developed as a high-definition system incorporating a high-resolution 64-electrode catheter, 3D ultra-high-density mapping capabilities and an algorithm that automates the signal capture and mapping processes.3,85

Each of the mentioned systems, except NavX, uses its catheters for high-density mapping. CARTO 3 uses the PentaRay catheter and the Rhythmia system uses the IntellaMap Orion catheter, while the NavX system allows the operator to use any available catheter.

Single and multielectrode acquisition techniques are clinically effective, whereas a trend towards multielectrode use has been observed in the mapping of complex arrhythmias, such as left AFL and scar-related VT.86 A pooled analysis of studies that compared fluoroscopy- with non-fluoroscopy-guided ablation of AF and AFL showed that non-fluoroscopic mapping and navigational systems yielded acute success rates not significantly different from fluoroscopy-guided ablation, while navigational systems resulted in a 10% relative reduction in the overall failure rate compared with fluoroscopy-guided ablation for the treatment of AF.87 Another interesting finding was that mapping systems were shown to reduce the arrhythmia burden and the need for antiarrhythmic drugs in patients with complex arrhythmia following a failed fluoroscopy-guided ablation procedure.87

Few studies in the literature have performed direct comparisons of the most commonly used mapping systems. Specifically, Liu et al. performed a direct comparison of CARTO-guided with EnSite/NavX-guided ablation of the PV in AF.88 They found that compared with the CARTO group, the EnSite/NavX group had a significantly higher acute success rate. Specifically, AF was terminated by radiofrequency delivery in 14 cases (35%) using EnSite/NavX system versus 5 cases (14%) in the CARTO system (p<0.05).88 In addition, complete PV isolation was achieved in 26 cases (65%) in the EnSite/NavX group versus 11 cases (31%) in the CARTO group (p<0.05), although contemporary techniques and outcomes have resulted in much higher success rates.88 On the other hand, Choo et al. did not find a significant difference in acute success rates between CARTO and NavX mapping systems in the setting of paroxysmal or persistent AF CA.12 In another study, the acute outcomes of AT ablation using standard (CARTO™ and NavX™) versus Rhythmia™ 3D high-density mapping systems were compared; in this setting, acute success rates were found to be similar for any system, leading to around 75% complete and 93% partial acute success rates in a highly selected population.89 Rottner et al. performed a direct comparison of CARTO and Rhythmia mapping systems in the setting of AF.90 This study showed that the Rhythmia mapping system had a significantly longer total mapping time, a longer total fluoroscopy time, more delivered RF applications and a longer total RF duration compared with the CARTO system, while there was no difference regarding the total ablation time, total procedure duration and acute procedural success.90 Another study evaluated the effect of Rhythmia in terms of the outcome of the second ablation for AF compared with the conventional method with an additional anatomical guide by the CARTO system.91 The authors have found that high-density mapping for the second ablation of AF was superior to the conventional ablation method in terms of the suppression of atrial events.91 Kaseno et al. evaluated PentaRay®/CARTO® 3 and Orion™/Rhythmia™ in LA voltage mapping.92 The study showed that the PentaRay map had a shorter procedure time than the Orion map, while a discrepancy in the evaluation of low-voltage areas between PentaRay and Orion maps was revealed.92

Finally, it should also be noted that while acute AF termination has been a common goal of AF ablation, in more recent years, the focus is more on a substrate ablation strategy (PVI and often additional ablation), and now the acute completeness of PVI and long-term freedom from arrhythmias are more typical endpoints.5

Limitations

We identified only a small number of studies27–51 on acute arrhythmia termination during CA procedures for the Rhythmia and NavX/EnSite mapping systems, especially in the setting of ventricular arrhythmias. Specifically, no data were revealed by the search strategy about the acute success rates in AF CA procedures using the Rhythmia mapping system, while only one study (Nayyar et al.) provided data about ischaemic VT for the EnSite mapping system.76 Furthermore, no data on the CardioInsight mapping system were retrieved.

It should be noted that Rhythmia is a more recently developed mapping system compared with CARTO and EnSite; therefore, the studies on Rhythmia included in this analysis are likely to be more recent, compared with studies on CARTO and EnSite and, therefore, could skew the results.

A quantitative synthesis to estimate the pooled success rate of each mapping system was not performed. With regard to AF, beyond PVI, there is no single established strategy; as a result, differences in success rates are also dependent on the ablation strategy. Furthermore, the type of AF (paroxysmal, persistent and long-standing persistent AF) also influences the success rate of the ablation procedure. Similarly, AT ablation is largely dependent on the underlying arrhythmia mechanism, atrial substrate and ablation strategy. With regard to the ventricular arrhythmias, both the type of cardiomyopathy and ablation strategy can influence the ablation outcomes. Ablation for VT is often performed during SR using substrate modification of local abnormal ventricular activities due to the hemodynamic instability associated with the arrhythmia.93 Therefore, our results cannot be extrapolated to procedures using substrate modification for ventricular arrhythmias.

We chose not to provide data about the procedural time presented in each study because this parameter is dependent on not only the technical characteristics of each system but also the operator’s skills. In addition, this review did not focus on the long-term arrhythmia recurrence rate because this marker is highly dependent on patients’ comorbidities, post-procedural medications, echocardiographic findings, follow-up strategy for the identification of arrhythmia recurrence, etc. It should be noted that acute success definitions differ slightly among the included studies (Tables 1 and 2), and this is an additional limitation that prevents the comparison of the efficacy of the different mapping systems in all clinical settings. Another cause of the noted discrepancy in success rates for each mapping system among the included studies could be related to the new features that were incorporated into each system and the different catheters that were used in the last few years.

Conclusions

Mapping systems have played a crucial role in high-density mapping and the observed high procedural success rates of atrial and ventricular CA procedures. More data are needed about the comparative efficacy of the different mapping systems across different clinical settings.

3

References

List View
Grid View
1
Copy DOIDOI Copied
Visit DOI Link

 Hindricks GPotpara TDagres Net alESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEur Heart J2021;373498DOI10.1093/eurheartj/ehaa798.

2
Copy DOIDOI Copied
Visit DOI Link

 Cronin EMBogun FMMaury Pet alHRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmiasHeart Rhythm2020;17:e2154DOI10.1016/j.hrthm.2019.03.002.

3
Copy DOIDOI Copied
Visit DOI Link

 Kim Y-HChen S-AErnst Set alAPHRS expert consensus statement on three-dimensional mapping systems for tachycardia developed in collaboration with HRS, EHRA, and LAHRSJ Arrhythm2020;36:21570DOI10.1002/joa3.12308.

4
Copy DOIDOI Copied
Visit DOI Link

 Calkins HBrugada JPacker DLet alHRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm SocietyEuropace2007;9:33579DOI10.1093/europace/eum120.

5
Copy DOIDOI Copied
Visit DOI Link

 Katritsis DMerchant FMMela Tet alCatheter ablation of atrial fibrillation the search for substrate-driven end pointsJ Am Coll Cardiol2010;55:22938DOI10.1016/j.jacc.2010.03.016.

6
Copy DOIDOI Copied
Visit DOI Link

 Hunter RJBerriman TJDiab Iet alLong-term efficacy of catheter ablation for atrial fibrillation: Impact of additional targeting of fractionated electrogramsHeart2010;96:13728DOI10.1136/hrt.2009.188128.

7
Copy DOIDOI Copied
Visit DOI Link

 Calkins Hel-Atassi RKalbfleisch SJet alEffect of operator experience on outcome of radiofrequency catheter ablation of accessory pathwaysAm J Cardiol1993;71:11045DOI10.1016/0002-9149(93)90581-v.

8
Copy DOIDOI Copied
Visit DOI Link

 Bazoukis GLetsas KPTse Get alPredictors of arrhythmia recurrence in patients with heart failure undergoing left atrial ablation for atrial fibrillationClin Cardiol2018;41:637DOI10.1002/clc.22850.

9
Copy DOIDOI Copied
Visit DOI Link

 Efremidis MLetsas KPGeorgopoulos Set alSafety, long-term outcomes and predictors of recurrence following a single catheter ablation procedure for atrial fibrillationActa Cardiol2019;74:31924. DOI10.1080/00015385.2018.1494114.

10
Copy DOIDOI Copied
Visit DOI Link

 Moher DLiberati ATetzlaff Jet alPreferred reporting items for systematic reviews and meta-analyses: The PRISMA statementPLoS Med2009;6:e1000097DOI10.1371/journal.pmed.1000097.

11
Copy DOIDOI Copied
Visit DOI Link

 Calvo DRubín JPérez DMorís CAblation of rotor domains effectively modulates dynamics of human: Long-standing persistent atrial fibrillationCirc Arrhythm Electrophysiol2017;10:12DOI10.1161/CIRCEP.117.005740.

12
Copy DOIDOI Copied
Visit DOI Link

 Choo WKFarwell DHarris SExperience of atrial fibrillation ablation in a new cardiac centre using three-dimensional mapping and multielectrode duty-cycled radiofrequency ablationArch Cardiovasc Dis2011;104:396402DOI10.1016/j.acvd.2011.05.003.

13
Copy DOIDOI Copied
Visit DOI Link

 Nademanee KMcKenzie JKosar Eet alA new approach for catheter ablation of atrial fibrillation: Mapping of the electrophysiologic substrateJ Am Coll Cardiol2004;43:204453DOI10.1016/j.jacc.2003.12.054.

14
Copy DOIDOI Copied
Visit DOI Link

 Seitz JHorvilleur JLacotte Jet alAutomated detection of complex fractionated atrial electrograms in substrate-based atrial fibrillation ablation: Better discrimination with a new setting of CARTO® algorithmJ Atr Fibrillation. 2013;6:673. DOI10.4022/jafib.673.

15
Copy DOIDOI Copied
Visit DOI Link

 Suleiman MGepstein LRoguin Aet alCatheter ablation of cardiac arrhythmias guided by electroanatomic imaging (CARTO): A single-center experienceIsr Med Assoc J2007;9:2604.

16
Copy DOIDOI Copied
Visit DOI Link

 Takahashi YYamashita SSuzuki Met alEfficacy of catheter ablation of focal sources in persistent atrial fibrillationJ Cardiovasc Electrophysiol2018;29:55965DOI10.1111/jce.13415.

17
Copy DOIDOI Copied
Visit DOI Link

 Wang XLiu XShi Het alHeart rhythm disorders and pacemakers: Pulmonary vein isolation combined with substrate modification for persistent atrial fibrillation treatment in patients with valvular heart diseases. Heart. 2009;95:177383. DOI10.1136/hrt.2007.124594.

18
Copy DOIDOI Copied
Visit DOI Link

 Wnuk-Wojnar A-MTrusz-Gluza MCzerwiński Cet alCircumferential pulmonary vein RF ablation in the treatment of atrial fibrillation: 3-year experience of one centreKardiol Pol2005;63:36270; .

19
Copy DOIDOI Copied
Visit DOI Link

 Wu JEstner HLuik Aet alAutomatic 3D mapping of complex fractionated atrial electrograms (CFAE) in patients with paroxysmal and persistent atrial fibrillationJ Cardiovasc Electrophysiol2008;19:897903DOI10.1111/j.1540-8167.2008.01145.x.

20
Copy DOIDOI Copied
Visit DOI Link

 Esato MHindricks GSommer Pet alColor-coded three-dimensional entrainment mapping for analysis and treatment of atrial macroreentrant tachycardiaHeart Rhythm2009;6:34958DOI10.1016/j.hrthm.2008.12.013.

21
Copy DOIDOI Copied
Visit DOI Link

 Jamil-Copley SLinton NKoa-Wing Met alApplication of ripple mapping with an electroanatomic mapping system for diagnosis of atrial tachycardiasJ Cardiovasc Electrophysiol2013;24:13619DOI10.1111/jce.12259.

22
Copy DOIDOI Copied
Visit DOI Link

 Okumura KSasaki SKimura Met alUsefulness of combined CARTO electroanatomical mapping and manifest entrainment in ablating adenosine triphosphate-sensitive atrial tachycardia originating from the atrioventricular node vicinityJ Arrhythm2016;32:13340DOI10.1016/j.joa.2015.11.004.

23
Copy DOIDOI Copied
Visit DOI Link

 Strisciuglio TVandersickel NLorenzo Get alProspective evaluation of entrainment mapping as an adjunct to new-generation high-density activation mapping systems of left atrial tachycardiasHeart Rhythm2020;17:2119DOI10.1016/j.hrthm.2019.09.014.

24
Copy DOIDOI Copied
Visit DOI Link

 Vicera JJBLin Y-JLee P-Tet alIdentification of critical isthmus using coherent mapping in patients with scar-related atrial tachycardiaJ Cardiovasc Electrophysiol2020;31:143647DOI10.1111/jce.14457.

25
Copy DOIDOI Copied
Visit DOI Link

 Wo H-TWen M-SChang P-Cet alSuccessful treatment of macroreentrant atrial tachycardia by radiofrequency ablation targeting channels with continuous activationPacing Clin Electrophysiol2014;37:92737. DOI10.1111/pace.12408.

26
Copy DOIDOI Copied
Visit DOI Link

 Yagishita ATakahashi YKawabata Met alUtility of a ripple map for the interpretation of atrial propagation during atrial tachycardiaJ Interv Card Electrophysiol2019;56:24957DOI10.1007/s10840-019-00638-4.

27
Copy DOIDOI Copied
Visit DOI Link

 Kitamura TMartin RDenis Aet alCharacteristics of single-loop macroreentrant biatrial tachycardia diagnosed by ultrahigh-resolution mapping systemCirc Arrhythm Electrophysiol2018;11:e005558DOI10.1161/CIRCEP.117.005558.

28
Copy DOIDOI Copied
Visit DOI Link

 Yamashita STakigawa MDenis Aet alPulmonary vein-gap re-entrant atrial tachycardia following atrial fibrillation ablation: An electrophysiological insight with high-resolution mappingEuropace2019;21:103947. DOI10.1093/europace/euz034.

29
Copy DOIDOI Copied
Visit DOI Link

 Anter EMcElderry THContreras-Valdes FMet alEvaluation of a novel high-resolution mapping technology for ablation of recurrent scar-related atrial tachycardiasHeart Rhythm2016;13:204855DOI10.1016/j.hrthm.2016.05.029.

30
Copy DOIDOI Copied
Visit DOI Link

 De Simone AAnselmino MScaglione Met alIs the mid-diastolic isthmus always the best ablation target for re-entrant atrial tachycardias J Cardiovasc Med (Hagerstown)2020;21:11322DOI10.2459/JCM.0000000000000923.

31
Copy DOIDOI Copied
Visit DOI Link

 Laţcu DGBun S-SViera Fet alSelection of critical isthmus in scar-related atrial tachycardia using a new automated ultrahigh resolution mapping systemCirc Arrhythm Electrophysiol. 2017;10:e004510. DOI10.1161/CIRCEP.116.004510.

32
Copy DOIDOI Copied
Visit DOI Link

 Takigawa MDerval NFrontera Aet alRevisiting anatomic macroreentrant tachycardia after atrial fibrillation ablation using ultrahigh-resolution mapping: Implications for ablationHeart Rhythm2018;15:32633. DOI10.1016/j.hrthm.2017.10.029.

33
Copy DOIDOI Copied
Visit DOI Link

 Takigawa MDerval NMaury Pet alComprehensive multicenter study of the common isthmus in post-atrial fibrillation ablation multiple-loop atrial tachycardiaCirc Arrhythm Electrophysiol. 2018;11:e006019. DOI10.1161/CIRCEP.117.006019.

34
Copy DOIDOI Copied
Visit DOI Link

 Aksu TGuler TEBozyel Set alInitial experience with fractionation mapping-guided ablation strategy in patients with long-standing persistent atrial fibrillationJ Interv Card Electrophysiol. 2021;61:40513. DOI10.1007/s10840-020-00834-7.

35
Copy DOIDOI Copied
Visit DOI Link

 Miyamoto KTsuchiya TNarita Set alBipolar Electrogram amplitudes in the left atrium are related to local conduction velocity in patients with atrial fibrillationEuropace2009;11:1597605DOI10.1093/europace/eup352.

36
Copy DOIDOI Copied
Visit DOI Link

 Miyamoto KTsuchiya TNagamoto Yet alCharacterization of bipolar electrograms during sinus rhythm for complex fractionated atrial electrograms recorded in patients with paroxysmal and persistent atrial fibrillation. Europace. 2010;12:494501. DOI10.1093/europace/euq033.

37
Copy DOIDOI Copied
Visit DOI Link

 Yamaguchi TTsuchiya TMiyamoto Ket alCharacterization of non-pulmonary vein foci with an EnSite array in patients with paroxysmal atrial fibrillationEuropace2010;12:1698706DOI10.1093/europace/euq326.

38
Copy DOIDOI Copied
Visit DOI Link

 Ammar-Busch SReents TKnecht Set alCorrelation between atrial fibrillation driver locations and complex fractionated atrial electrograms in patients with persistent atrial fibrillationPacing Clin Electrophysiol2018;41:127985DOI10.1111/pace.13483.

39
Copy DOIDOI Copied
Visit DOI Link

 Kumagai KSakamoto TNakamura Ket alCombined dominant frequency and complex fractionated atrial electrogram ablation after circumferential pulmonary vein isolation of atrial fibrillationJ Cardiovasc Electrophysiol. 2013;24:97583. DOI10.1111/jce.12166.

40
Copy DOIDOI Copied
Visit DOI Link

 Kumagai KMinami KKutsuzawa DOshima SEvaluation of the characteristics of rotational activation at high-dominant frequency and complex fractionated atrial electrogram sites during atrial fibrillationJ Arrhythm. 2017;33:4955. DOI10.1016/j.joa.2016.05.008.

41
Copy DOIDOI Copied
Visit DOI Link

 Lin YJTai CTChang SLet alEfficacy of additional ablation of complex fractionated atrial electrograms for catheter ablation of nonparoxysmal atrial fibrillationJ Cardiovasc Electrophysiol2009;20:60715DOI10.1111/j.1540-8167.2008.01393.x.

42
Copy DOIDOI Copied
Visit DOI Link

 Lo L-WLin Y-JTsao H-Met alThe impact of left atrial size on long-term outcome of catheter ablation of chronic atrial fibrillationJ Cardiovasc Electrophysiol2009;20:12116DOI10.1111/j.1540-8167.2009.01546.x.

43
Copy DOIDOI Copied
Visit DOI Link

 Matsuo SYamane TDate Tet alSubstrate modification by pulmonary vein isolation and left atrial linear ablation in patients with persistent atrial fibrillation: Its impact on complex-fractionated atrial electrogramsJ Cardiovasc Electrophysiol2012;23:96270DOI10.1111/j.1540-8167.2012.02322.x.

44
Copy DOIDOI Copied
Visit DOI Link

 Nair MNayyar SRajagopal Set alResults of radiofrequency ablation of permanent atrial fibrillation of >2 years duration and left atrial size >5 cm using 2-mm irrigated tip ablation catheter and targeting areas of complex fractionated atrial electrogramsAm J Cardiol2009;104:6838DOI10.1016/j.amjcard.2009.04.042.

45
Copy DOIDOI Copied
Visit DOI Link

 Nakahara SHori YKobayashi Set alEpicardial adipose tissue-based defragmentation approach to persistent atrial fibrillation: Its impact on complex fractionated electrograms and ablation outcomeHeart Rhythm2014;11:134351DOI10.1016/j.hrthm.2014.04.040.

46
Copy DOIDOI Copied
Visit DOI Link

 Roux J-FGojraty SBala Ret alEffect of pulmonary vein isolation on the distribution of complex fractionated electrograms in humans. Heart Rhythm. 2009;6:15660. DOI10.1016/j.hrthm.2008.10.046.

47
Copy DOIDOI Copied
Visit DOI Link

 Suenari KLin Y-JChang S-Let alRelationship between arrhythmogenic pulmonary veins and the surrounding atrial substrate in patients with paroxysmal atrial fibrillationJ Cardiovasc Electrophysiol2011;22:40510. DOI10.1111/j.1540-8167.2010.01932.x.

48
Copy DOIDOI Copied
Visit DOI Link

 Verma ALakkireddy DWulffhart Zet alRelationship between complex fractionated electrograms (CFE) and dominant frequency (DF) sites and prospective assessment of adding DF-guided ablation to pulmonary vein isolation in persistent atrial fibrillation (AF)J Cardiovasc Electrophysiol2011;22:130916DOI10.1111/j.1540-8167.2011.02128.x.

49
Copy DOIDOI Copied
Visit DOI Link

 Narita SMiyamoto KTsuchiya Tet alRadiofrequency catheter ablation of atrial tachycardia under navigation using the EnSite arrayCirc J2010;74:132231DOI10.1253/circj.cj-09-1008.

50
Copy DOIDOI Copied
Visit DOI Link

 Patel AMd’Avila ANeuzil Pet alAtrial tachycardia after ablation of persistent atrial fibrillation: Identification of the critical isthmus with a combination of multielectrode activation mapping and targeted entrainment mapping. Circ Arrhythm Electrophysiol2008;1:1422DOI10.1161/CIRCEP.107.748160.

51
Copy DOIDOI Copied
Visit DOI Link

 Nagamoto YTsuchiya TMiyamoto Ket alAtrial tachycardia during ongoing atrial fibrillation ablation. – EnSite array analysisCirc J2011;75:10809DOI10.1253/circj.cj-10-0742.

52
Copy DOIDOI Copied
Visit DOI Link

 Luther VLinton NWFJamil-Copley Set alA prospective study of ripple mapping the post-infarct ventricular scar to guide substrate ablation for ventricular tachycardiaCirc Arrhythm Electrophysiol. 2016;9:e004072. DOI10.1161/CIRCEP.116.004072.

53
Copy DOIDOI Copied
Visit DOI Link

 Marai ISuleiman MBlich Met alClinical and electrophysiologic outcomes of patients undergoing percutaneous endocardial ablation of scar-related ventricular tachycardia: A single-center experienceIsr Med Assoc J. 2010;12:66770.

54
Copy DOIDOI Copied
Visit DOI Link

 Volkmer MOuyang FDeger Fet alSubstrate mapping vs. tachycardia mapping using CARTO in patients with coronary artery disease and ventricular tachycardia: Impact on outcome of catheter ablation. Europace. 2006;8:96876. DOI10.1093/europace/eul109.

55
Copy DOIDOI Copied
Visit DOI Link

 Antz MBerodt KBänsch Det alCatheter-ablation of ventricular tachycardia in patients with coronary artery disease: Influence of the endocardial substrate size on clinical outcomeClin Res Cardiol2008;97:1107. DOI10.1007/s00392-007-0596-7.

56
Copy DOIDOI Copied
Visit DOI Link

 Bogun FKrishnan SSiddiqui Met alElectrogram characteristics in postinfarction ventricular tachycardia: Effect of infarct ageJ Am Coll Cardiol2005;46:66774DOI10.1016/j.jacc.2005.01.064.

57
Copy DOIDOI Copied
Visit DOI Link

 Brunckhorst CBDelacretaz ESoejima Ket alIdentification of the ventricular tachycardia isthmus after infarction by pace mappingCirculation2004;110:6529DOI10.1161/01.CIR.0000138107.11518.AF.

58
Copy DOIDOI Copied
Visit DOI Link

 Deneke TGrewe PHLawo Tet alSubstrate-modification using electroanatomical mapping in sinus rhythm to treat ventricular tachycardia in patients with ischemic cardiomyopathyZ Kardiol2005;94:45360. DOI10.1007/s00392-005-0240-3.

59
Copy DOIDOI Copied
Visit DOI Link

 Dinov BSchönbauer RWojdyla-Hordynska Aet alLong-term efficacy of single procedure remote magnetic catheter navigation for ablation of ischemic ventricular tachycardia: A retrospective studyJ Cardiovasc Electrophysiol2012;23:499505DOI10.1111/j.1540-8167.2011.02243.x.

60
Copy DOIDOI Copied
Visit DOI Link

 Kettering KWeig HJReimold Met alCatheter ablation of ventricular tachycardias in patients with ischemic cardiomyopathy: Validation of voltage mapping criteria for substrate modification by myocardial viability assessment using FDG PETClin Res Cardiol2010;99:75360DOI10.1007/s00392-010-0182-2.

61
Copy DOIDOI Copied
Visit DOI Link

 Li YGGrönefeld GIsrael Cet alStepwise approach to substrate modification of ventricular tachycardia after myocardial infarctionChin Med J (Engl)2006;119:11829.

62
Copy DOIDOI Copied
Visit DOI Link

 Jamil-Copley SVergara PCarbucicchio Cet alApplication of ripple mapping to visualize slow conduction channels within the infarct-related left ventricular scarCirc Arrhythm Electrophysiol2015;8:7686. DOI10.1161/CIRCEP.114.001827.

63
Copy DOIDOI Copied
Visit DOI Link

 Verma AMarrouche NFSchweikert RAet alRelationship between successful ablation sites and the scar border zone defined by substrate mapping for ventricular tachycardia post-myocardial infarctionJ Cardiovasc Electrophysiol2005;16:46571DOI10.1046/j.1540-8167.2005.40443.x.

64
Copy DOIDOI Copied
Visit DOI Link

 Miyamoto KNoda TSatomi Ket alLarger low voltage zone in endocardial Unipolar map compared with that in epicardial bipolar map indicates difficulty in eliminating ventricular tachycardia by catheter ablationHeart Vessels2016;31:133746DOI10.1007/s00380-015-0732-7.

65
Copy DOIDOI Copied
Visit DOI Link

 Yamashina YYagi TNamekawa Aet alDistribution of successful ablation sites of idiopathic right ventricular outflow tract tachycardiaPacing Clin Electrophysiol2009;32:72733DOI10.1111/j.1540-8159.2009.02358.x.

66
Copy DOIDOI Copied
Visit DOI Link

 Parreira LCavaco DReis-Santos Ket alRemote magnetic navigation for mapping and ablation of right and left ventricular outflow tract arrhythmiasRev Port Cardiol2013;32:48995DOI10.1016/j.repc.2012.12.012.

67
Copy DOIDOI Copied
Visit DOI Link

 Yamashina YYagi TNamekawa Aet alClinical and electrophysiological difference between idiopathic right ventricular outflow tract arrhythmias and pulmonary artery arrhythmiasJ Cardiovasc Electrophysiol2010;21:1639DOI10.1111/j.1540-8167.2009.01601.x.

68
Copy DOIDOI Copied
Visit DOI Link

 Tovia-Brodie OBelhassen BGlick Aet alUse of new imaging CARTO(R) Segmentation Module software to facilitate ablation of ventricular arrhythmiasJ Cardiovasc Electrophysiol2017;28:2408DOI10.1111/jce.13112.

69
Copy DOIDOI Copied
Visit DOI Link

 Verma AKilicaslan FSchweikert RAet alShort- and long-term success of substrate-based mapping and ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasiaCirculation2005;111:320916. DOI10.1161/CIRCULATIONAHA.104.510503.

70
Copy DOIDOI Copied
Visit DOI Link

 Satomi KKurita TSuyama Ket alCatheter ablation of stable and unstable ventricular tachycardias in patients with arrhythmogenic right ventricular dysplasiaJ Cardiovasc Electrophysiol2006;17:46976DOI10.1111/j.1540-8167.2006.00434.x.

71
Copy DOIDOI Copied
Visit DOI Link

 Martin CATakigawa MMartin Ret al“Use of novel electrogram “Lumipoint” algorithm to detect critical isthmus and abnormal potentials for ablation in ventricular tachycardia.”JACC Clin Electrophysiol2019;5:4709. DOI10.1016/j.jacep.2019.01.016.